As the genomic region containing the Bcl-2-related ovarian killer (BOK) locus is frequently deleted in certain human cancers, BOK is hypothesized to have a tumor suppressor function. In the present study, we analyzed primary non-small-cell lung carcinoma (NSCLC) tumors and matched lung tissues from 102 surgically treated patients. We show that BOK protein levels are significantly downregulated in NSCLC tumors as compared to lung tissues (p < 0.001). In particular, we found BOK downregulation in NSCLC tumors of grades two (p 5 0.004, n 5 35) and three (p 5 0.031, n 5 39) as well as in tumors with metastases to hilar (pN1) (p 5 0.047, n 5 31) and mediastinal/subcarinal lymph nodes (pN2) (p 5 0.021, n 5 18) as opposed to grade one tumors (p 5 0.688, n 5 7) and tumors without lymph node metastases (p 5 0.112, n 5 51). Importantly, in lymph node-positive patients, BOK expression greater than the median value was associated with longer survival (p 5 0.002, Mantel test). Using in vitro approaches, we provide evidence that BOK overexpression is inefficient in inducing apoptosis but that it inhibits TGFbinduced migration and epithelial-to-mesenchymal transition (EMT) in lung adenocarcinoma-derived A549 cells. We have identified epigenetic mechanisms, in particular BOK promoter methylation, as an important means to silence BOK expression in NSCLC cells. Taken together, our data point toward a novel mechanism by which BOK acts as a tumor suppressor in NSCLC by inhibiting EMT. Consequently, the restoration of BOK levels in low-BOK-expressing tumors might favor the overall survival of NSCLC patients.
within the nuclear compartment 2, 11 and nonapoptotic roles in regulation of proliferation, 12 and even protective roles in response to specific stressors or in specialized cell types have been proposed. 2, 15 Recently, it was shown that-unexpectedly-the BOK gene is relatively frequently deleted in human cancers. 16 BOK might therefore have a previously unrecognized tumor suppressor function. Lung cancers, 80% of which are NSCLC type tumors, remain the leading cause of cancer-related deaths worldwide. 17 Importantly, NSCLCs are well-known to develop high resistance toward chemo-and radiotherapy and patients often relapse because of progression of the primary tumor to metastatic disease. In this study, we investigated the tumor suppressor potential of BOK and its possible molecular function(s) in NSCLC cells and tissues. The results of our study show that high levels of BOK in primary NSCLC tumors correlate with longer overall survival of NSCLC patients and that BOK plays a role in the epithelial-to-mesenchymal transition and migration of NSCLC cells, whereas it might only play a minor role in apoptosis induction.
Materials and Methods

Reagents
High-glucose Dulbecco's Modified Eagle Medium (DMEM with GlutaMAX), trypsin-EDTA solution and penicillin/ streptomycin stock solutions were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Fetal calf serum (FCS, Sera Pro, ultralow endotoxin) was purchased from Pan Biotech (Aidenbach, DE). RPMI 1640 AQmedia TM and 4-hydroxytamoxifen (4-OHT) were from Sigma Aldrich Chemie GmBH (Buchs, Switzerland).
NSCLC patients
Specimens of NSCLC tumors and matched nontransformed lung parenchyma were obtained from 102 patients who did not receive radiotherapy or chemotherapy before surgery for lung cancer. Patients are characterized in Supporting Information, S1. The study was approved by the local institutional ethical committee and was conducted in accordance with the Declaration of Helsinki. Signed written informed consent was obtained from each patient before entry to the study. Tissue samples (1 g, wet mass) from non-necrotic parts of the tumor and from the lung at a site located as distantly as possible from the tumor, were excised from the resected lung lobe or lung immediately after surgery. All tissues were snapfrozen in liquid nitrogen and stored at 2808C until protein and RNA extraction. The histopathological classification of the tumors was done according to the World Health Organization criteria 18 and tumor staging was performed according to the international pTNM system. 19 
NSCLC cell lines
NSCLC cell lines used in this study were derived from squamous cell lung carcinoma: CALU-1, NCI-H520, SKMES-1, lung adenocarcinoma: A549, SKLU-1, LXF-289, COLO-699, and large-cell lung carcinoma: NCI-H1299, LCLC-103H, CORL23. CALU-1, SKMES-1, A549 and SKLU-1 cells were obtained from the European Collection of Cell Cultures (Salisbury, UK), LXF-289 and COLO-699 cells were obtained from The German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) and NCI-H520 and NCI-H1299 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cell lines were cultured in humidified atmosphere of 5% CO 2 and air at 378C in DMEM or RPMI containing 10% heat-inactivated FCS, 10 5 IU/l penicillin-G and 100 mg/l streptomycin.
Quantitative real-time RT-PCR analysis
Total RNA isolation, reverse transcription and PCR amplification were performed as described earlier. 20, 21 The BOK (GeneBank accession no. NM_032515) mRNA-directed primers were: forward 5 0 -CAGTCTGAGCCTGTGGTGAC-3 0 , reverse 5 0 -TGATGCCTGCAGAGAAGATG-3 0 . b-Actin was used as reference gene (GeneBank accession no. NM_001101) using the primers: forward: 5 0 -CTGGCACCCAGCACAATG-3 0 , reverse: 5 0 -GGGCCGGACTCGTCATAC-3 0 . Cell cycle regulatory gene expression was assessed using the Human Cell Cycle Primer Library (Biomol GmbH, Hamburg, DE).
Protein extraction and immunoblotting
Protein lysates from NSCLC cell lines were prepared in RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% Triton-X100, 0.5% Na-deoxycholate, 0.1% SDS, 1 mM EDTA) supplemented with a protease inhibitor cocktail (Complete, Roche, Basel, Switzerland), 1 mg/ml pepstatin, 2 mM Na 3 VO 4 and 50 mM NaF. Total protein was determined by BCA Assay (Thermo Fisher Scientific, Waltham, MA, USA). Protein extracts from frozen tissue samples were prepared as described previously. 21 Protein extracts were boiled for 5 min
What's new? Bcl-2-related ovarian killer (BOK) is one of the most frequently deleted Bcl-2 family members in human cancer. Here the authors identify a possible cell death-independent tumor suppressor function of BOK. They find that BOK is epigenetically silenced and that its overexpression decreases anchorage-independent growth in non-small-cell lung carcinoma (NSCLC). In vivo, BOK levels were predictive of survival in lymph node-positive patients, pointing to BOK expression as a new prognostic marker in later stage NSCLC. 
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Cell death analysis by flow cytometry
Viability was determined by flow cytometry using FITCAnnexin V/PI exclusion as previously described. 2 Data were acquired using FACS-Calibur flow cytometer (BD Biosciences) and analyzed using VenturiOne software (Applied Cytometry Systems).
Immunofluorescence
A549GEV16/BOK cells were seeded on sterile glass coverslips. After attachment, 100 nM of 4-OHT was added to induce BOK expression. The following day, cells were treated with or without 10 ng/ml of TGF-b2 for 48 h. Immunofluorescence staining was performed as described in Ref. 2) and washed twice with IFA. Finally, DAPI was added to the cells at a concentration of 8 mg/ml and plates were measured the next day on Fortessa flow cytometer (BD Biosciences). FITC, APC and PE Calibrite beads (BD Biosciences) were used for compensation settings along with cells stained with DAPI alone. Acquired data were analyzed using VenturiOne software (Applied Cytometry Systems) and clusters were generated in SysStat (San Jose, CA, USA).
CRSIPR/Cas9-and shRNA-mediated downregulation of BOK
The BOK genomic locus was edited using CRISPR/Cas9 technology producing H1299, A549 and LFX-289 cells devoid of detectable BOK protein expression. The lentiCRISPR v2 plasmid was a gift from Feng Zhang (Addgene plasmid #52961). 22 The following gRNA sequences targeting the exon 2 of human BOK was designed using the publicly available service at http://crispr.mit.edu: gRNA2: Fw 5 0 -caccgAAA GGCGTCCATGATCTCGG-3 0 and Rev 5 0 -aaacCCGAGA TCATGGACGCCTTTc 23 0 ; gRNA3: Fw 5 0 -caccgGTCTG TGGGCGAGCGGTCAA-3 0 and Rev 5 0 -aaacTTGACCGCTC GCCCACAGACc-3 0 . HEK 293 T cells were transfected with the plasmids lentiCRISPR v2 (minus gRNA for control), pMD2GVSV-G, psPAX2 using X-tremeGENE HP DNA Transfection Reagent (Roche). Viruses were harvested after 24 h, filtered and freshly added to semi-confluent cultures of H1299, A549 and LXF-289 cells in the presence of 8 lg/mL polybrene, followed by 3 weeks of selection with 2 mg/mL puromycin. BOK downregulation was achieved using Mission TM lentiviral plasmids (Sigma-Aldrich) expressing (shRNA targeting human Bok (5 0 -CCGGCCGCTTCC TGAAGGCTGCCTTCTCGAGAAGGCAGCCTTCAGGAA GCGGTTTTTG-3 0 ) and nontargeting shRNA control (shC002). Plasmids were transiently co-transfected with pMD2GVSV-G and pCMVdR8.2 into HEK293T cells using X-tremeGENE HP DNA Transfection Reagent (Roche Diagnostics). After 48 h, viral supernatant was harvested and freshly used to transduce H1299 cells in the presence of 8 lg/mL polybrene, followed by selection with 2 lg/mL puromycin for 2 weeks.
Chromatin immunoprecipitation (ChIP) (Fig. 1a) . A representative image of BOK protein expression using nearinfrared fluorophores for quantitative western blot analysis is shown in Figure 1d . Additionally, BOK protein was equally downregulated in tumors in men (p 5 0.012; n 5 67, Wilcoxon signed rank test) and in women (p 5 0.029; n 5 35, Wilcoxon signed rank test) (Fig. 1a) . Of note, BOK protein was downregulated in smokers (p < 0.001; n 5 88, Wilcoxon signed rank test) but not in nonsmokers (p 5 0.326; n 5 14, Wilcoxon signed rank test), as compared to the paired lung tissue (Fig. 1a) . Moreover, BOK protein was decreased in less differentiated tumors, that is, grades 2 (p 5 0.004, n 5 35, Wilcoxon signed rank test) and 3 (p 5 0.031, n 5 39, Wilcoxon signed rank test) as compared to the well differentiated matched lungs.
We observed a decrease of BOK protein expression in stage III NSCLC as compared to the matched nonaffected lungs (p 5 0.005; n 5 23; Wilcoxon signed rank test). As staging is categorized according to the pTNM system, 19 we analyzed whether BOK levels varied with tumor invasion to lymph nodes (pN). We found that in primary tumors with no spread to lymph nodes, there was no difference in BOK levels when compared to the control tissues (p 5 0.112, n 5 51, Wilcoxon signed rank test). However, lower BOK protein levels were detected in primary tumor cells spreading to nearby lymph nodes (pN1) (p 5 0.047, n 5 31, Wilcoxon signed rank test) and even less in tumors spreading to lymph nodes in mediastinum and/or around the carina (pN2) (p 5 0.021, n 5 18, Wilcoxon signed rank test) (Fig. 1b) .
Next, we analyzed the relationship between BOK expression and a prognostic relevance for patient survival. Interestingly, BOK protein was weakly correlated with overall survival of lymph node-positive NSCLC patients (p 5 0.0173, n 5 24; Spearman's correlation) (Fig. 1c) .
BOK expression is predictive of survival in lymph nodepositive patients As BOK expression was weakly correlated with survival time in our patient group (Fig. 1c ), we asked whether BOK level was predictive of survival. Patients (n 5 39) were stratified by BOK expression: less than the median or equal to or greater
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than the median. When all patients were analyzed, the effect of BOK was not statistically significant (p 5 0.62, Mantel test). However, when analysis was limited to patients with lymph node involvement (n 5 24, Fig. 2 
BOK expression is regulated by epigenetic mechanisms in NSCLC cells
We further investigated whether the variable levels of BOK mRNA detected in NSCLC cell lines (Fig. 3 ) might be due to transcriptional silencing via epigenetic mechanisms. Using the software MethPrimer, 23 we found an evolutionary conserved CpG island in the BOK promoter region extending into the second exon of the BOK gene (Fig. 3a) . As expected from in silico analysis, treatment with the DNA methyltransferase inhibitor 5-aza-2 0 -deoxycytidine (decitabine) significantly increased BOK mRNA level in all 10 NSCLC cell lines studied (Fig. 3b) . Co-treatment with trichostatin A further upregulated BOK mRNA in 6 out of 10 cell lines (Fig. 3b) . By methylation-specific PCR, we confirmed that methylation occurs directly in the BOK gene of NSCLC cells displaying low BOK levels (A549 and COLO-699), whereas no promoter methylation was detectable in the high BOK expressing H1299 cells (Fig. 3c) . ChIP analysis confirmed that the histone cores of the nucleosomes surrounding the BOK gene are deacetylated in A549 cells, which can be reversed by the histone class I and II deacetylase inhibitor trichostatin A (Fig.  3d) . The combined treatment with decitabine did not further increase the H3K9 acetylation ( Fig. 3d and Supporting Information, S5) implying that BOK promoter methylation and histone deacetylation are not dependent on one another. This was confirmed by ChIP analysis of DNA-dependent RNA polymerase II, which revealed that single treatments with either decitabine or trichostatin A are able to re-express the BOK gene. However, the combined treatment had synergistic effects for the gene re-expression (Fig. 3d) , which correlated with mRNA levels (Fig. 3b) . BOK protein was markedly elevated in 5 of 10 studied cell lines upon decitabine treatment. In fact, BOK protein was upregulated >2 times in COLO-699, COR-L23, A549 and NCI-H520 cells (Fig. 3e) . Trichostatin A increased BOK protein in the same cells except for COLO-699 (Fig. 3e) .
The lack of correlation between BOK mRNA and protein levels may be partially explained by a previously reported high BOK protein turnover. 1 However, as shown in Figure   4a , treatment of NSCLC cell lines with bortezomib, a specific 26S proteasome inhibitor, led to stabilization of BOK protein only in 2 out of 10 NSCLC cell lines (A549 and COLO-699).
BOK overexpression does not induce significant apoptosis and does not sensitize toward drug-induced apoptosis in NSCLC cells
To investigate the role of BOK in NSCLC cell death, we used a 4-hydroxytamoxifen (4-OHT)-inducible system to overexpress BOK in A549 cells. 2 Despite readily detectable protein levels ( Fig. 4b) , enforced BOK expression in A549 cells did not induce cell death, nor did it sensitize to cell death induced by cisplatin, etoposide, staurosporine (STS), fludarabine (FDB), TRAIL or 5-fluorouracil (5-FU) as assessed by flow cytometry using FITC-AnnexinV/PI staining ( Fig. 4c ) and enzymatic caspase-3/-7 activity assay (data not shown).
Loss of BOK negatively impacts on cellular proliferation rate in NSCLC cells
Interestingly, we noticed that BOK downregulation by RNA interference and disruptive BOK gene editing using CRISPR/ Cas9 (Fig. 4b) , decreased the proliferation rate of NSCLC cells, but not the number of dead cells as assessed by trypan blue exclusion (Fig. 4d) . Cells lacking BOK proliferated significantly slower, as confirmed by MTT assay (Supporting Information, S2). Of note, besides prominent expression in the cytoplasm, we also detected significant amounts of BOK protein in purified nuclear fractions in 8 out of 10 cell lines (Fig. 4e) . Interestingly, upon downregulation of BOK, hardly any signal for the protein was detectable in the nuclear compartments (Fig. 4f) , which correlated with decreased proliferation. This was accompanied by a significant increase of p16 INK4A and p19 INK4D cell cycle inhibitors (Fig. 4g ). On the other hand, BOK overexpression did not influence the proliferation of A549 cells ( Fig. 4d and Supporting Information, S2). Interestingly, however, BOK overexpression in A549 cells inhibited 7-day anchorage independent growth in soft agar (Fig. 4h) .
Role of BOK in epithelial-to-mesenchymal transition
To investigate a possible role of BOK in epithelial-tomesenchymal transition (EMT), we treated cells with TGFb2, an inducer of a mesenchymal cell state through the activation of SMAD2. We performed western blot and immunofluorescence analyses to verify the EMT marker expression. In A549 cells exposed to 10 ng/ml of TGF-b2 for 48 h, the mesenchymal marker vimentin was upregulated (Figs. 5a and  5d ). On the other hand, an epithelial marker, E-cadherin, was downregulated (Figs. 5a and 5d ). However, A549 cells overexpressing BOK did not lose E-cadherin after TGF-b2 treatment (Figs. 5a and 5d ). Enforced expression of BOK in A549 cells treated with TGF-b2 did not only diminish expression of the full length 120 kDa E-cadherin, but also of its 132 kDa precursor, suggesting not a proteolytic cleavage but rather regulation of its expression. These data indicate that BOK prevents the downregulation of E-cadherin. Moreover, morphological analysis revealed that BOK overexpression significantly abrogated TGF-b2-induced EMT (Fig. 5b) . Consistent with this interpretation, BOK inhibited TGF-b2-induced cell migration, as assessed by Boyden chamber migration assay (Fig. 5c) . Furthermore, we detected TGFb2-induced increase of ATF4 as well as a shorter form of BOK that lacks the N-terminus due to alternative translation initiation at Met (15)13 ; ATF4, being required for cell invasion, 24 was slightly diminished in TGFb2-treated cell upon additional BOK overexpression and was accompanied by reduction of the shorter form of BOK (Fig. 5e) . Given the possible involvement of BOK in antagonizing EMT, we performed protein expression profiling by flow cytometry. We screened A549GEV16/BOK cells treated with or without TGF-b and with or without 4-OHT for the expression of 238 surface proteins (Supporting Information, S3). Flow cytometry data were analyzed as previously described 25 with minor modifications. We used standardized percent of positive events and standardized mean fluorescence intensity of positive events for K-means clustering algorithm. Furthermore, double weight was given to percentage of positive events. Flow cytometry data for the expression of proteins that changed with the treatments are shown in Supporting Information, S4. Specifically, TGF-b alone upregulated EGFR and downregulated CD141, CD164, CD24, CD326 (EpCAM), CD38, Lymphotoxinb receptor, MET, CD49f, CD54, CD70, CD71, CD321 (F11 Receptor) (Fig. 6) .
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However, enforced BOK expression abrogated TGFbinduced upregulation of EGFR and downregulation of MET and CD321. BOK alone upregulated MET and had a downmodulating effect on the expression of CD166, CD49f, Lymphotoxinb Receptor, CD70, CD71 (TfR1) and CD94 (Fig. 6 ).
Discussion
We and others have recently shown that BOK is widely expressed and detectable at the protein level in the mouse, with highest levels found in reproductive organs, brain and gastrointestinal tract, but also in the lung. 1, 2, 9 On the other hand, BOK mRNA expression seems to be downregulated in many human cancer cell lines. [26] [27] [28] Interestingly, Beroukhim et al. identified somatic copy number alterations (deletions) of the BOK gene locus in a wide screen of human primary cancers and cancer cell lines. 16 These findings point toward a possible tumor suppressor function of BOK. In this study, we found that BOK is not deleted at the genomic level in any of the 10 NSCLC cell lines studied. However, in BOK lowexpressing cell lines, we identified an epigenetic silencing mechanism. Specifically, the DNA-methyltransferase inhibitor decitabine upregulated BOK mRNA in all 10 cell lines tested up to 13.8-fold (Fig. 3b) . Furthermore, combination of decitabine with the histone deacetylase inhibitor trichostatin A had a synergistic effect on BOK mRNA induction in 6 out of 10 cells (Fig. 3b) . Our ChIP analysis revealed that the combined treatment of decitabine and trichostatin A has no synergistic effect on histone acetylation (Fig. 3d and Supporting Information, S5), implying that repression of the BOK gene occurs directly by methylation of CpG dinucleotides near the transcriptional start site of BOK (Fig. 3b) , thereby blocking the binding of transcription factors and not by recruitment of transcriptional repressors such as methyl-binding proteins that are associated with histone deacetylases.
Such epigenetic silencing might contribute to tumorigenesis as already shown for some BH3-only proteins, 29 and also to tumor metastasis. While BOK had no effect on acceleration of Em-myc induced pre-B/B cell lymphoma, which is likely explained by the very low expression of BOK in lymphocytes, 9 loss of BOK may slow NSCLC tumorigenesis as BOK downregulation by RNA interference or CRISPR/Cas9 mediated gene editing resulted in significantly slower proliferation of NSCLC cells, correlating with loss of detection of nuclear BOK and increase of cell cycle inhibitors p16 INK4A and p19 INK4D (Figs. 4dg and Supporting Information, S2). Given the prominent BOK localization in the nucleus, 2, 11 it is therefore attractive to speculate that the nuclear BOK may interact with the cell cycle machinery, as proposed by Ray et al. in the context of trophoblast proliferation. 12 Interestingly, the observed role of BOK in regulating proliferation opposes the cell-cycle-specific roles described for the antiapoptotic BCL-2 family members BCL-2 and BCL-X L , which were shown to inhibit cell cycle progression to G1 by upregulation of p27. 30, 31 On the other hand, we show that BOK may have the potential to inhibit metastatic spread of developing NSCLC tumor cells by interfering with EMT (Fig. 5) . Unfortunately, the majority of NSCLC patients are diagnosed with advanced disease. 17, 32 Patients with high-grade disease more often have a higher stage at diagnosis, a greater probability of recurrence or metastasis, and an overall shorter survival time after diagnosis. 19 Although our patient population was heterogeneous, with patients ranging from Stage IA to IV, all were considered candidates for surgical resection. BOK expression level only appeared to impact survival in patients with lymph node involvement at the time of surgery. In this patient group, increased BOK protein expression was associated with significantly longer survival times (Fig. 2) . Importantly, we found that BOK levels were significantly decreased in tumors of lymph node-positive patients and in less differentiated tumors compared to adjacent lung parenchyma (Fig. 1b) . This phenotype might be favoured by epigenetic mechanisms during tumor progression (Fig. 3) 33 and/or by proteasomedependent regulation of BOK levels. 1,13 Importantly, we found a poor correlation between BOK mRNA and protein levels. However, our data indicate that mechanisms other than proteasomal turnover may be crucial to control BOK levels and activity in NSCLC cells (Fig. 4a) . The process by which cancer cells metastasize is thought to involve the transition of tumor cells with an epithelial phenotype to cells with mesenchymal traits. This process is accompanied with loss of tight junction proteins such as Ecadherin and upregulation of transcriptional repressors of tight junction proteins such as Twist, Snail or Slug. The resulting loss in polarity enables tumor cells to migrate and seed distant lesions. There is evidence concerning the involvement of the tumor microenvironment in EMT. 34, 35 It was previously shown, that certain cytokines such as IL-6, IL-8 or TGFb initiate and/or sustain the mesenchymal cancer cell state. [36] [37] [38] We used TGFb to induce EMT in A549 cells, which express low levels of endogenous BOK. When exogenous BOK expression was induced in those cells, TGFbinduced phenotypic change was prevented (Fig. 5 ). Along the same line, enforced BOK expression significantly diminished anchorage-independent growth in soft agar (Fig. 4h) , and reduced TGFb-induced transmigration (Fig. 5c) . Importantly, these effects are independent of BOK-induced cell death, as we showed that overexpression of BOK does not induce apoptosis in A549 cells ( Fig. 4d and Supporting Information, S2). It is also worthwhile mentioning that A549 cells have acquired a dysfunction in the apoptosome machinery in the procaspase-9 activation probably by inhibitory phosphorylation of procaspase-9. 39 We and others have shown that BOK mainly localizes to the endoplasmic reticular membrane and BOK has accordingly been implicated with the regulation of ER stress, ERAD pathway and unfolded protein response (UPR). 1,2,6 Whereas we did not find BOK to affect the ATF6 or IRE1a arms of the UPR (not shown), our data show that BOK is likely involved in the modulation of the PERK > ATF4 arm in the context of TGFb induced EMT, supporting studies that link PERK to EMT. 24 Furthermore, the quantitative surface proteomics profiling showed upregulation of EGFR by TGFb (Fig. 6 ) suggesting the involvement of JUN N-terminal kinases pathway leading to JUN transcription factor activation 40 that binds to EGFR responsive element. Although enforced expression of BOK abrogated EGFR upregulation (Fig. 6) , which is indispensable for AKT activation leading to cell survival, BOK also abrogated TGFbmediated MET downregulation. However, sustained expression of MET and CD321 in TGFb-treated BOK overexpressing cells shows epithelial state of the cells, thus confirming the BOK role in EMT inhibition. Moreover, overexpression of BOK downregulated membrane expression of CD166/ ALCAM (Fig. 6) , which is implicated in NSCLC cancer cells migration and invasion in vitro 41 and its reduced expression inhibited skeletal metastasis in prostate cancer in vivo.
42
In conclusion, we found that alteration of BOK expression in NSCLC tumors could account for differences in tumor invasion and thus overall survival of NSCLC patients.
